12 results on '"Tuah, Wilson"'
Search Results
2. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions
- Author
-
Alan Knell, Thomas Berko, Linda Lehman, Tuah Wilson, Sarah Eyangoh, Kingsley Asiedu, Ernest Opoku, Kristien Velding, Edwin Ampadu, Jérôme Robert, Estelle Marion, Bright Osei-Wusu, Annick Chauty, Edward Sarpong, William Faber, Anastasia Nsiah, Ambroise Adeye, Yaw Ampem Amoako, Marie Françoise Ardent, William Thompson, George Amofa, Richard Phillips, Line Ganlonon, John M Macdonald, Elliot Koranteng Tannor, Till F. Omansen, Raymond Omollo, Terry Treadwell, Justice Abotsi, Albert Paintsil, Nanaa Francisca Sarpong, Samuel Osei Mireku, Maxime Kiki, Raoul Saizonou, David Ofori-Adjei, Bernadette Agbavor, Godfred Sarpong, Espoir Sodjinou, Michael Ochieng Otieno, Fred Stephen Sarfo, Paul Saunderson, Aloysius Dzibordzi Loglo, Martial Kindjinou, Justice K. Boakye-Appiah, Beatrice Konadu, Arnaud Yamadjako, Didier Agossadou, Mark Forson, Tjip S. van der Werf, Sally-Ann Ohene, Elizabeth Ofori, Mathias Ndogyele, Ymkje Stienstra, Thaddaeus Egondi, Richard Asamoah-Frimpong, Joseph Ken Adu Poku, Mabel Sarpong-Duah, Joyce Mensah-Bonsu, Felicity Aboagye, Thierry Gateau, Michael Frimpong, Joseph Ofori Nyarko, Mark Wansbrough-Jones, Kabiru Mohamed Abass, Clémence Guegnard, Alexandre Tiendrebeogo, Akpolan, Jacques H. Grosset, Sandor-Adrian Klis, Naomi Adanmado Gersande, Bernardo, Elizabeth, Identification and development of vaccine candidates for Buruli Ulcer Disease - BURULIVAC - - EC:FP7:HEALTH2010-03-01 - 2013-05-31 - 241500 - VALID, Kwame Nkrumah University of Science and Technology [GHANA] (KNUST), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Agogo Presbyterian Hospital [GHANA], NkawieToaso Government Hospital [GHANA], Centre de diagnostic et de traitement de la lèpre et de l’Ulcère de Buruli Madeleine et Raoul Follereau [Pobè, Bénin], Drugs for Neglected Diseases initiative [Nairobi, Kenya] (ARO), Africa Regional Office [Nairobi, Kenya], National Buruli ulcer Control Programme [Accra, Ghana] (GHS), Ghana Health Service [Accra, Ghana], Programme National de Lutte contre la lèpre et l’Ulcère de Buruli [Cotonou, Benin], ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), St George's, University of London, Johns Hopkins University (JHU), University of Miami Leonard M. Miller School of Medicine (UMMSM), Institute for Advanced Wound Care [Montgomery, AL, USA], American Leprosy Missions [Greenville, SC, USA], Korle-BU Teaching Hospital [Accra, Ghana], WHO, Country Office for Benin [Cotonou, Benin], WHO, Regional Office for Africa [Brazzaville, Republic of the Congo], WHO, Country Office for Ghana [Accra, Ghana], University Medical Center Groningen [Groningen] (UMCG), Department of Neglected Tropical Diseases, WHO [Geneva, Switzerland], WHO sponsored the study with additional support in cash or kindprovided by MAP International, American Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, SanofiPasteur France, and BuruliVac (EU FP7-241500)., European Project: 241500,EC:FP7:HEALTH,FP7-HEALTH-2009-single-stage,BURULIVAC(2010), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Microbes in Health and Disease (MHD), and Kwame Nkrumah University of Science and Technology (KNUST)
- Subjects
Male ,Buruli ulcer ,Administration, Oral ,030204 cardiovascular system & hematology ,Ghana ,DISEASE ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Clarithromycin ,INFECTION ,Clinical endpoint ,Benin ,Medicine ,EPIDEMIOLOGY ,030212 general & internal medicine ,Child ,Buruli Ulcer ,education.field_of_study ,biology ,General Medicine ,Anti-Bacterial Agents ,3. Good health ,Tolerability ,Mycobacterium ulcerans ,Streptomycin ,MYCOBACTERIUM-ULCERANS ,Drug Therapy, Combination ,Female ,Rifampin ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Young Adult ,03 medical and health sciences ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Internal medicine ,Humans ,education ,COMBINATION ,Wound Healing ,business.industry ,medicine.disease ,biology.organism_classification ,EFFICACY ,Regimen ,Delayed-Action Preparations ,business - Abstract
BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions.METHODS: We did an open-label, non-inferiority, randomised (1:1 with blocks of six), multicentre, phase 3 clinical trial comparing fully oral RC8 with RS8 in patients with early, limited Buruli ulcer lesions. There were four trial sites in hospitals in Ghana (Agogo, Tepa, Nkawie, Dunkwa) and one in Benin (Pobè). Participants were included if they were aged 5 years or older and had typical Buruli ulcer with no more than one lesion (caterories I and II) no larger than 10 cm in diameter. The trial was open label, and neither the investigators who took measurements of the lesions nor the attending doctors were masked to treatment assignment. The primary clinical endpoint was lesion healing (ie, full epithelialisation or stable scar) without recurrence at 52 weeks after start of antimicrobial therapy. The primary endpoint and safety were assessed in the intention-to-treat population. A sample size of 332 participants was calculated to detect inferiority of RC8 by a margin of 12%. This study was registered with ClinicalTrials.gov, NCT01659437.FINDINGS: Between Jan 1, 2013, and Dec 31, 2017, participants were recruited to the trial. We stopped recruitment after 310 participants. Median age of participants was 14 years (IQR 10-29) and 153 (52%) were female. 297 patients had PCR-confirmed Buruli ulcer; 151 (51%) were assigned to RS8 treatment, and 146 (49%) received oral RC8 treatment. In the RS8 group, lesions healed in 144 (95%, 95% CI 91 to 98) of 151 patients, whereas lesions healed in 140 (96%, 91 to 99) of 146 patients in the RC8 group. The difference in proportion, -0·5% (-5·2 to 4·2), was not significantly greater than zero (p=0·59), showing that RC8 treatment is non-inferior to RS8 treatment for lesion healing at 52 weeks. Treatment-related adverse events were recorded in 20 (13%) patients receiving RS8 and in nine (7%) patients receiving RC8. Most adverse events were grade 1-2, but one (1%) patient receiving RS8 developed serious ototoxicity and ended treatment after 6 weeks. No patients needed surgical resection. Four patients (two in each study group) had skin grafts.INTERPRETATION: Fully oral RC8 regimen was non-inferior to RS8 for treatment of early, limited Buruli ulcer and was associated with fewer adverse events. Therefore, we propose that fully oral RC8 should be the preferred therapy for early, limited lesions of Buruli ulcer.FUNDING: WHO with additional support from MAP International, American Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, Sanofi-Pasteur, and BuruliVac.
- Published
- 2020
3. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial
- Author
-
Nienhuis, Willemien A, Stienstra, Ymkje, Thompson, William A, Awuah, Peter C, Abass, K Mohammed, Tuah, Wilson, Awua-Boateng, Nana Yaa, Ampadu, Edwin O, Siegmund, Vera, Schouten, Jan P, Adjei, Ohene, Bretzel, Gisela, and van der Werf, Tjip S
- Published
- 2010
- Full Text
- View/download PDF
4. Randomised Trial to Compare Clarithromycin (Extended Release)-Rifampicin and Streptomycin-Rifampicin for Early, Limited Lesions of M. Ulcerans Infection
- Author
-
Richard O. Phillips, Jérôme Robert, K. Mohamed Abass, William Thompson, Fred Stephen Sarfo, Tuah Wilson, Godfred Sarpong, Thierry Gateau, Annick Chauty, Raymond Omollo, Michael Ochieng Otieno, Thaddaeus Wandera Egondi, Edwin O. Ampadu, Didier Agossadou, Estelle Marion, Line Ganlonon, Mark Wansbrough-Jones, Jacques Grosset, John M. Macdonald, Terry Treadwell, Paul Saunderson, Albert Paintsil, Linda Lehman, Michael Frimpong, Francisca Nanaa Sarpong, Raoul Saizonou, Alexandre Tiendrebeogo, Sally-Ann Ohene, Ymkje Stienstra, Kingsley B. Asiedu, Tjip van der Werf, and Buruli Ulcer Clinical Trial Study Team
- Subjects
Buruli ulcer ,medicine.medical_specialty ,biology ,business.industry ,Tropical disease ,Antimicrobial ,medicine.disease ,biology.organism_classification ,Clinical trial ,Streptomycin ,Clarithromycin ,Internal medicine ,Mycobacterium ulcerans ,medicine ,business ,Rifampicin ,medicine.drug - Abstract
Background Buruli ulcer (Mycobacterium ulcerans infection) is a Neglected Tropical Disease characterised by severe subcutaneous necrosis, with occasional bone involvement. Being reported from 33 countries, it is most prevalent in West and Central Africa, and Australia. In Africa, the major burden is borne by poor rural children. If left untreated, Buruli ulcer may progress to cause severe suffering and ultimately stigmatising disability resulting in school drop-out and loss of income. Standard antimicrobial treatment with oral rifampicin 10 mg/kg and intramuscular streptomycin 15 mg/kg for eight weeks (RS8) is highly effective but streptomycin injections are painful and may cause hearing loss. Methods Between January 2013 and December 2017, we conducted an open label randomised multicentre phase III clinical trial with noninferiority design comparing fully oral treatment with rifampicin and clarithromycin 15 mg/kg extended release (RC8) with RS8. A sample size of 332 participants was calculated to detect inferiority of CR8 by a margin of 12%.%%%%An article published by The Lancet%%%%KNUST
- Published
- 2019
5. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load
- Author
-
Frimpong, Michael, primary, Agbavor, Bernadette, additional, Duah, Mabel Sarpong, additional, Loglo, Aloysius, additional, Sarpong, Francisca N., additional, Boakye-Appiah, Justice, additional, Abass, Kabiru M., additional, Dongyele, Mathias, additional, Amofa, George, additional, Tuah, Wilson, additional, Frempong, Margaret, additional, Amoako, Yaw A., additional, Wansbrough-Jones, Mark, additional, and Phillips, Richard O., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease
- Author
-
Justice Abotsi, Kingsley Asiedu, William Thompson, Mark Forson, Mohammed K. Abass, Richard Phillips, Tuah Wilson, Mark Wansbrough-Jones, Fred S. Sarfo, and Yaw Ampem Amoako
- Subjects
Buruli ulcer ,medicine.medical_specialty ,medicine.drug_class ,Antibiotics ,Disease ,Gastroenterology ,Internal medicine ,Clarithromycin ,medicine ,polycyclic compounds ,Pharmacology (medical) ,Pharmacology ,biology ,business.industry ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,biology.organism_classification ,Surgery ,Infectious Diseases ,Streptomycin ,Susceptibility ,Mycobacterium ulcerans ,Positive culture ,Erratum ,business ,After treatment ,medicine.drug - Abstract
Buruli ulcer, an ulcerating skin disease caused by Mycobacterium ulcerans infection, is common in tropical areas of western Africa. We determined the clinical and microbiological responses to administration of rifampin and streptomycin for 2 weeks followed by administration of rifampin and clarithromycin for 6 weeks in 43 patients with small laboratory-confirmed Buruli lesions and monitored for recurrence-free healing. Bacterial load in tissue samples before and after treatment for 6 and 12 weeks was monitored by semiquantitative culture. The success rate was 93%, and there was no recurrence after a 12-month follow-up. Eight percent had a positive culture 4 weeks after antibiotic treatment, but their lesions went on to heal. The findings indicate that rifampin and clarithromycin can replace rifampin and streptomycin for the continuation phase after rifampin and streptomycin administration for 2 weeks without any apparent loss of efficacy.
- Published
- 2014
7. Short Report: Serum Levels of Neopterin during Antimicrobial Treatment for Mycobacterium ulcerans Infection
- Author
-
de Zeeuw, Janine, Duggirala, Sridevi, Nienhuis, Willemien A., Abass, K. Mohammed, Tuah, Wilson, Omansen, Till F., van der Werf, Tjip S., Stienstra, Ymkje, and Microbes in Health and Disease (MHD)
- Subjects
immune system diseases ,LEPROSY ,HUMANS ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,PROCALCITONIN ,DISEASE ,BURULI ULCER - Abstract
Neopterin is closely associated with activation of the cellular immune system. Neopterin levels differed between controls and patients with Buruli ulcer disease. No differences between patients with or without paradoxical responses were observed. Therefore, neopterin has no value in detecting paradoxical responses among patients with limited Buruli ulcer disease. Neopterin levels were lower in patients receiving clarithromycin. This finding might indicate a slower cellular immune recovery, with possible consequences in future therapy with clarithromycin.
- Published
- 2013
8. Wound Care in Buruli Ulcer Disease in Ghana and Benin
- Author
-
Velding, Kristien, primary, Klis, Sandor-Adrian, additional, Abass, Kabiru M., additional, Tuah, Wilson, additional, Stienstra, Ymkje, additional, and van der Werf, Tjip, additional
- Published
- 2014
- Full Text
- View/download PDF
9. Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial
- Author
-
Klis, Sandor, primary, Ranchor, Adelita, additional, Phillips, Richard O., additional, Abass, Kabiru M., additional, Tuah, Wilson, additional, Loth, Susanne, additional, Velding, Kristien, additional, van der Werf, Tjip S., additional, and Stienstra, Ymkje, additional
- Published
- 2014
- Full Text
- View/download PDF
10. Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug Trial
- Author
-
Klis, Sandor, primary, Stienstra, Ymkje, additional, Phillips, Richard O., additional, Abass, Kabiru Mohammed, additional, Tuah, Wilson, additional, and van der Werf, Tjip S., additional
- Published
- 2014
- Full Text
- View/download PDF
11. Serum Levels of Neopterin during Antimicrobial Treatment for Mycobacterium ulcerans Infection
- Author
-
de Zeeuw, Janine, primary, Abass, K. Mohammed, additional, Nienhuis, Willemien A., additional, Duggirala, Sridevi, additional, Stienstra, Ymkje, additional, van der Werf, Tjip S., additional, Omansen, Till F., additional, and Tuah, Wilson, additional
- Published
- 2013
- Full Text
- View/download PDF
12. Antimicrobial treatment for early, limited Mycobacterium ulceransinfection: a randomised controlled trial
- Author
-
Nienhuis, Willemien A, Stienstra, Ymkje, Thompson, William A, Awuah, Peter C, Abass, K Mohammed, Tuah, Wilson, Awua-Boateng, Nana Yaa, Ampadu, Edwin O, Siegmund, Vera, Schouten, Jan P, Adjei, Ohene, Bretzel, Gisela, and van der Werf, Tjip S
- Abstract
Surgical debridement was the standard treatment for Mycobacterium ulceransinfection (Buruli ulcer disease) until WHO issued provisional guidelines in 2004 recommending treatment with antimicrobial drugs (streptomycin and rifampicin) in addition to surgery. These recommendations were based on observational studies and a small pilot study with microbiological endpoints. We investigated the efficacy of two regimens of antimicrobial treatment in early-stage M ulceransinfection.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.